sintilimab + etoposide + cisplatin

Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that targets programmed cell death protein 1 (PD-1), blocking its interaction with PD-L1 and PD-L2 to restore endogenous antitumor T-cell responses. It is developed for use in various cancers, including classical Hodgkin's lymphoma and non-small cell lung cancer. Etoposide is a small molecule topoisomerase II inhibitor used as chemotherapy, while cisplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in cancer cells. The combination of sintilimab with etoposide and cisplatin represents an immunotherapy plus chemotherapy regimen under investigation primarily for solid tumors such as non-small cell lung cancer[1][4][8].

Brand names

Tyvyt + etoposide + cisplatin

Other names

anti-PD-1 monoclonal antibody IBI308anti-PD1 monoclonal antibody IBI308anti-PD 1 monoclonal antibody IBI308sintilimab